Leading Edge Genomic Services & Solutions

Novogene Receives CFDA Approval for NovoFocus NSCLC CDx Test

Beijing, China – August 15, 2018 – Tianjin Novogene Bioinformatics Technology Company LTD, a fully-owned subsidiary of Novogene Co., received CFDA approval for its NovoFocus NSCLC CDx Test today. This is a next-generation sequencing (NGS)-based diagnostic test that simultaneously analyzes tumor samples for multiple genomic mutations associated with several CFDA-approved targeted therapies for non-small cell lung cancer (NSCLC), which accounts for ~80% of all lung cancers in China.

The NovoFocus NSCLC CDx Test was developed on the Thermo Fisher Ion Proton™ sequencing platform (approved by CFDA as “DA8600” in January 2017 for the diagnosis of cancer and inherited diseases). The reagent kits for sample processing and library construction, as well as the data analysis and result reporting software system, were developed by Novogene. Following this CFDA approval, results from the sequencing and analysis of three genes, EGFR, ALK and ROS1, can be used to identify NSCLC patients who may be eligible for treatment by CFDA-approved targeted therapies Gefitinib (IRESSA®), Osimertinib (TAGRISSO®) and Crizotinib (XALKORI®), respectively. Results on the other three genes, KRAS, BRAF and PIK3CA, can be considered by clinicians together with other test results and the patient’s disease characteristics during clinical decision making.

Figure: CFDA announcement for the approval of the NovoFocus NSCLC CDx Test (red box: translated to English below)

Ion Proton™ is a registered trademark of Thermo Fisher; IRESSA® and TAGRISSO® are registered trademarks of AstraZeneca; and XALKORI® is a registered trademark of Pfizer.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Establishes its First European Genomic Sequencing Center in Cambridge, UK

Cambridge, UK – May 21, 2018 – Novogene, a leading global provider of genomics services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe.

The Novogene UK Genomic Sequencing Center will be equipped with a full automation system and the latest Illumina NovaSeq and supercomputing platforms. Establishing this facility will enable Novogene to provide cutting-edge next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies, and biotechnology companies.

“We are proud to set up our first European laboratory at the Babraham Research Campus,” said Dr. Ruiqiang Li, Founder and CEO of Novogene. “Our UK lab is our first step towards addressing the increasing demand from our European customers and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”

Derek Jones, CEO of Babraham Bioscience Technologies, which is responsible for the management and development of the Babraham Research Campus added: “I am extremely pleased to welcome Novogene to the Babraham Research Campus. The role of genomics is rapidly evolving and the Cambridge Cluster has become a hub for innovation in this area, attracting leader organizations, like Novogene, to locate here. Close proximity to academic and commercial collaborateors – both on campus and within the wider cluster – is hugely beneficial to the organizations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”

About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit: www.babraham.com.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:
Tingting Zhou
General Manager
Novogene Europe
zhoutingting@novogene.com

The Babraham Research Campus
Derek Jones
CEO
Babraham Bioscience Technologies Ltd
derek.jones@babraham.co.uk

Novogene Receives CLIA Certification for its Clinical Laboratory in Sacramento, California

Sacramento, California – May 1, 2018 – Novogene, a leading global provider of genomic services and solutions, announced that it successfully obtained CLIA certification for its clinical laboratory on March 27, 2018.

The Clinical Laboratory Improvement Amendments (CLIA) are the US federal regulatory standards that apply to US facilities that test human specimens for diagnosis, prevention or treatment of disease or other health assessment. CLIA regulations require clinical laboratories to be certified by their state and the Centers for Medicare and Medicaid Services (CMS) before they can accept human samples for clinical testing. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) support the regulations of CLIA and play unique roles in assuring quality laboratory testing. An important objective of the CLIA is to ensure the accuracy, reliability and timeliness of clinical test results.

The process of CLIA certification includes inspections of the following: specimen collection, sample transportation, sample preparation and storage, laboratory platforms, assay validation, instrument and reagent calibration, quality assessment and proficiency testing, laboratory biosafety inspection, and onsite audit of laboratory environment, staff, and management system. Novogene’s Sacramento laboratory has passed all the above inspections and demonstrated its assay’s reliable performance.

The CMS also evaluates the performance characteristics of a laboratory’s bioinformatics analysis pipeline. Novogene’s bioinformatics pipeline integrates public data with its in-house database. With its comprehensive database and bioinformatics pipeline, Novogene is able to deliver clinical-grade genomic testing.

According to Dr. David Jiang, General Manager of Clinical and Consumer Genomics at Novogene, “CLIA certification is an important milestone for Novogene, allowing us to provide genomic solutions not only for scientific research, but also for clinical testing. We are excited to offer our clinical partners high-quality sequencing services at low cost with fast turn-around time. Our goal is to democratize sequencing in the clinical space.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com

Novogene prepares to enter the proteomics service market with the addition of five Thermo Scientific™ Q Exactive™ HF-X Mass Spectrometers

San Diego and Beijing, October 5, 2017 — Novogene, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, recently announced the stationing of five Thermo Scientific™ Q Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ Mass Spectrometers in its Tianjin laboratory. With this addition, the company will be able to begin offering proteomic services. Novogene is committed to building the world’s most advanced biological mass spectrometry center to provide customers with comprehensive and in-depth multi-omics solutions.

The Q Exactive™ HF-X Mass Spectrometer uses a high-capacity transfer tube for maximum ion loading, an electrodynamic ion funnel that accommodates and transmits ions over a broader mass range, and a high-field Thermo Scientific™ Orbitrap™ mass analyzer. The platform significantly improves the scanning speed to an unprecedented 40Hz, the sensitivity by up to 10 times, as well as the quantitative reproducibility and sample throughput of protein detection. These features make the Q Exactive™ HF-X better-suited for the in-depth study of proteomics of complex biological samples.

As a world-leading sequencing services provider, Novogene has shown unsurpassed strength and capacity in genomic services and solutions since its founding in 2011. With the addition of five high-resolution Q Exactive™ HF-X Mass Spectrometers, Novogene has marked its transition from a genetic sequencing service company to a full service, multi-omics solution provider to better serve its customers worldwide and to enhance the quality of scientific research and precision medicine.

“Novogene has been focusing on applying high-throughput sequencing technologies in the field of scientific research over the years, and has become the world’s largest next-generation and SMRT sequencing center,” said Dr. Zhi Jiang, President of Novogene. “Proteomics is closer to the dynamic changes in life activities and phenotypic variation. With the continuous development of the mass spectrometry technology, we have seen a growing demand for multi-omics research. We have had a long-term collaboration in genomic sequencing and molecular diagnostics with Thermo Fisher already and we look forward to this in-depth cooperation to jointly promote the development of proteomics in the life sciences research with Thermo Fisher.”

Novogene’s services cover scientific research, cancer gene detection and genetic testing areas. With the largest sequencing capacity and gene interpretation capabilities worldwide, Novogene has provided genomic sequencing and bioinformatics data analysis services to global customers in research universities, research institutes, hospitals, pharmaceutical R&D companies and agricultural companies. Novogene is committed to promoting the rapid development and application of proteomics in the scientific research services area using the advanced high-resolution mass spectrometry platforms and solutions from Thermo Fisher.

Contacts:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The Global Ant Genomics Alliance Announces Partnership With Novogene To Advance The Genomic Study Of Ants Around The World

July 18, 2017, Copenhagen, Denmark and Beijing, China –– The Global Ant Genomics Alliance (GAGA; http://antgenomics.dk/), an international collaboration of researchers from a variety of fields and institutions from across the globe, is partnering with Novogene Co., LTD, a leading global provider of genomic services and solutions, to make a significant leap forward in understanding the genomics of ants.

The partnership aims to obtain around 300 genomes, covering all ant genera across the world, to facilitate reconstruction of the evolutionary history and ecological resilience of this important social insect family. Under the partnership Novogene will provide PacBio sequencing for the ant species collected by the GAGA consortium and deliver high quality long-reads data, with up to 50x coverage generating 15 gigabases of long-read data for each ant genome.

“PacBio sequencing technology will allow almost gap-less genome assemblies that should make sure that ant genomes generated under GAGA will meet future quality standards of journals and repositories,” said Guojie Zhang, professor at the University of Copenhagen and head of the GAGA consortium. “The technology also requires only small amounts of DNA, significantly alleviating the biomass constraints for sampling material and enabling genome sequencing for almost all rare and small ants.”

“We are pleased to be partnering with The Global Ant Genomics Alliance on this important research endeavor,” said Dr. Ruiqiang Li, Founder, Chairman, and CEO of Novogene. “By applying our PacBio sequencing capabilities to the project we look forward to generating a robust database on the ant genome and helping advance the knowledge and understanding of this diverse species.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the World. Novogene pursues scientific excellence, strong commitment to customer service, and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top-tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

About The Global Ant Genomics Alliance
The Global Ant Genome Project is a growing international collaboration of researchers from a variety of fields and institutions across the world. This global project on ant genomics will provide a comprehensive dataset of the genomic diversity of the world’s ant genera. Based on the comparative analysis of these data, we will be able to understand the global trends of ant evolution and narrow down the genetic features that have been particularly relevant for the diversification and astonishing evolutionary success of ants. Researchers are interested in joining the consortium
can submit their research interest via http://antgenomics.dk/call-for-gaga-projects-and-subprojects/. For more information, click here.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene Will Use Pacific Biosciences SMRT Technology to Build Novo-Disease SV Genomes Database

–First database of long-read whole genome sequencing data–

San Diego, July 18, 2017 — Novogene announced today it plans to use Pacific Biosciences SMRT® technology to build a comprehensive Chinese genome database, Novo-Disease SV Genomes. The database will consist of long-read sequencing data of 1000 Chinese genomes from a variety of disease types. As the first ever database of long-read human whole genome sequencing information, Novo-Disease SV Genomes will be a breakthrough step in the understanding of the human genome and in the field of precision medicine.

As a pioneer in the genomics field, Novogene has previously constructed the Novo-Zhonghua Genomes database, a population-specific genome database that consists of whole genome sequencing data on 2,500 normal Chinese genomes. The Novo-Zhonghua Genomes database reveals a large amount of SNPs and InDels that can be used for disease-specific variant annotation.

Databases such as Novo-Zhonghua Genomes, constructed with a large amount of genome sequencing data, lay the foundation for precision medicine. However, a genome database consisting of short-read sequencing data alone often misses the information on most structural variants (SVs), the changes in the chromosomal structure that can be linked to disease susceptibility.

Pacific Biosciences’ Single Molecule, Real-Time (SMRT) sequencing technology has the advantage of uniform coverage across all genomes. Whole genome sequencing with PacBio Systems helps provide complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

“By applying PacBio’s SMRT technology to the construction of our Novo-Disease SV Genomes database, we will be able to apply long-read sequencing that can detect disease variants often missed by short-read sequencing,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “This more revealing and informative database should greatly improve our understanding of disease mechanisms and contribute to the development of novel diagnostic and therapeutic approaches.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/

Contacts:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

Novogene NGS Medical Lab Receives CAP Accreditation

April 4, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced that its next-generation sequencing (NGS) medical lab in Tianjin, China has received accreditation from the College of American Pathologists (CAP). With CAP accreditation, Novogene now will be able to provide its high-quality, well-established clinical sequencing services to customers throughout the world.

The process of CAP accreditation involves a rigorous series of inspections and certifications on lab quality management systems, experimental processes, data analysis and clinical interpretation. CAP accreditation, received on March 30th, 2017, attests to Novogene Tianjin medical lab’s global comparability and competitiveness for NGS sample quality control, personnel qualification, facilities, and quality assurance.

Novogene established its clinical service division in January 2014, and has continuously developed its clinical services in China, including tumor gene detection and genetic testing services. Novogene also established a Precision Medicine Center of Excellence with Thermo Fisher Scientific in December 2016 and is one of the first China National Genetic Testing Technology Demonstration Centers.

“Our strategy is to incorporate scientific research, clinical diagnostics, and preventive medicine synergistically to drive life science research and improve human healthcare,” stated Dr. Ruiqiang Li, CEO of Novogene. “CAP accreditation represents an important milestone for our Tianjin medical center, which can now provide superior clinical services to our more than 450 hospital customers and pharmaceutical partners globally for projects of any scale, in ways that we could not before.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journals such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene receives the 2017 Innovation and Excellence Award from Corporate LiveWire

We are proud to announce that Novogene and our Founder and CEO Ruiqiang Li have been honored with a 2017 Innovation and Excellence Award from Corporate LiveWire, a UK-based provider of business information to the corporate finance sector. The Innovation & Excellence Awards give recognition to businesses that are transforming their respective industries and the standard-bearers of excellence by continually setting industry trends as well as showing significant advances in terms of innovation and improvement.

The Innovation and Excellence Awards are sponsored by The International Business Innovation Association (InBIA), a global non-profit member network that serves a diverse group of 2,200+ entrepreneurship centers. InBIA helps guide, mentor and develop sustainable entrepreneurial programs in every industry and demographic around the globe. In selecting Novogene and Dr. Li, the judging panel at Corporate LiveWire cited the way Novogene has embraced advanced technology, including its use of Illumina HiSeq and PacBio Sequel systems, as integral to the company’s success. The panel also cited Novogene’s dedication to scientific excellence, customer service, data quality, highly trained team and extensive portfolio of patents and publications as key differentiators for the company.

Novogene Completes USD $75 Million [515 Million RMB] B Round Financing

San Diego and Beijing, November 30, 2016 — Novogene Technology Co., Ltd., a leading commercial provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and bioinformatics expertise, announced today that it has completed a USD $75 Million [515 Million RMB] B round financing with China Merchants Bank Co., Ltd.’s CMB International Capital Management (Shenzhen) Co., Ltd. (“CMB International”), SDIC Innovation Investment Management Co., Ltd. (“SDIC Innovation”) and Shanghai Sigma Square Investment Center LP (“Sigma Square Capital”).

Novogene, headquartered in Beijing with the largest genomic sequencing center in the Asia-Pacific region, has labs in Tianjin and the U.S., and subsidiaries or joint ventures in Hong Kong, the U.S. (Novogene Corporation headquartered in San Diego), U.K. and Singapore. In addition to its industry-leading NGS service capabilities, Novogene has established a clinical lab in China that meets US CLIA and CAP standards, where it provides tumor gene detection and genetic testing services to patients, hospitals and pharmaceutical companies in China.

The Series B financing will support strategic growth in Novogene’s global NGS service market and in clinical sequencing R&D and services. Additionally, funds from the financing will be used to enhance operating efficiency to further strengthen the company’s leadership position in the NGS industry.

“We welcome the participation of our valued investors and are honored by their support and confidence in the future of our company,” stated Novogene CEO Dr. Ruiqiang Li. “Since being founded in 2011, Novogene has rapidly emerged as a global leader in genomics and bioinformatics, pioneering the application of biology, computer science and information technology in animal and plant research as well as human health. This financing will enable us to continue to build on that momentum”

About CMB International
CMB International, a wholly-owned subsidiary of China Merchants Bank (“CMB”), provides comprehensive high-quality financial services to institutional and corporate clients as well as individual investors. CMB International acts as the only direct investment platform of CMB, responsible for leveraging the domestic large emerging financial market with domestic and overseas capital. CMB International specializes in private equity investment, investment fund management, mezzanine fund management, cross-border capital operations and other financial services.

About SDIC Innovation
SDIC Innovation is an independent professional private equity management institution managing 50 billion RMB in assets. SDIC Innovation, which manages financial institution funds, social security funds and state-owned and private capital, is one of the largest professional private equity management institutions [in China]. SDIC innovation, focuses on discovering and creating enterprise value, striving to unify the interests of invested enterprises, existing shareholders and investors.

About Sigma Square Capital
Founded in 2016, Sigma Square Capital is an investment institution focused on high-growth emerging industries. Sigma Square Capital is an early stage investor in the emerging fields of healthcare, technology, finance and consumer products. The two founding partners, Kun Ouyang and Dai Zhang, have led media, medical and health field investments for many years for IDG Capital.

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 43 NGS related patents, and over 200 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services.

For more information, visit https://en.novogene.com/

Media Contact:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com